Login to Your Account



A LOSE-LOSE SITUATION?

Chinese biopharma firms listed in U.S. SEC audit crisis

By Kristine Yang
Staff Writer

Wednesday, February 26, 2014

HONG KONG – A recent ruling by the U.S. SEC banning Big Four accounting firms from performing audits linked to China could spell trouble for Chinese biopharmaceutical companies listed in the U.S. The ban is not yet in force pending an appeal.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription